Selank is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as a derivative of the endogenous peptide tuftsin. Registered in Russia for the treatment of anxiety and phobic disorders, Selank occupies a unique position in the nootropic peptide space: it reduces anxiety without sedation, dependency, or the cognitive blunting associated with benzodiazepines. For researchers studying anxiolytic mechanisms or stress resilience, it's one of the most pharmacologically interesting tools available.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Selank primarily reduces anxiety through GABA-A receptor modulation and enkephalin stabilisation. Unlike benzodiazepines, it produces calming effects without sedation, cognitive blunting, or dependency risk. Additional effects include improved mood, stress resilience, and mild cognitive enhancement. A second key mechanism involves stabilisation of enkephalins — endogenous opioid peptides that regulate mood, pain, and stress response. Selank also modulates serotonin metabolism and has shown BDNF upregulation similar to Semax, though less pronounced. Selank was developed and clinically tested in Russia through the 1990s and 2000s, with the Institute of Molecular Genetics leading its research program. A notable finding was improvement in learning and memory alongside anxiety reduction, which is the opposite of what benzodiazepines typically produce. In animal models, Selank demonstrated antidepressant effects, improved immune function (via tuftsin-related immunomodulatory activity), and neuroprotective effects in stress models. Selank has one of the most benign side effect profiles of any nootropic peptide.
How Does Selank Work?
Selank's primary anxiolytic effect involves modulation of GABA-A receptors — the same receptors targeted by benzodiazepines. However, Selank acts as a modulator rather than a direct agonist, producing calming effects without the receptor downregulation, tolerance, and withdrawal that characterise benzodiazepine dependence. This allosteric modulation preserves the natural homeostatic tone of GABA-A signaling rather than forcing constant activation, which explains the lack of tolerance development in research and clinical observations.
A second key mechanism involves stabilisation of enkephalins — endogenous opioid peptides that regulate mood, pain, and stress response. Selank inhibits enkephalin-degrading enzymes (specifically neprilysin and other peptidase enzymes), prolonging the activity of these natural mood-stabilising compounds. This enkephalin stabilisation contributes to Selank's reported improvements in emotional resilience and stress tolerance. By preserving endogenous enkephalin levels, Selank provides mood elevation without exogenous opioid administration — a significant safety advantage.
Selank also modulates serotonin metabolism and has shown BDNF (brain-derived neurotrophic factor) upregulation similar to Semax, though less pronounced. The mechanism for BDNF enhancement appears to involve upregulation of TrkB receptor expression — the high-affinity receptor for BDNF. In animal models, chronic Selank administration increased BDNF gene expression in the hippocampus and prefrontal cortex, regions critical for mood regulation and cognitive resilience. This BDNF elevation may contribute to long-term neuroplastic effects, explaining why some users report sustained mood improvements and improved stress adaptation even after discontinuation.
The net pharmacological profile — GABA modulation + enkephalin stabilisation + serotonin effects + BDNF upregulation — explains why users report reduced anxiety, improved mood, and cognitive clarity simultaneously. Unlike antidepressants that typically take weeks to reach efficacy, Selank's anxiolytic effects are often noted within 30 minutes to a few hours of administration, consistent with its acute modulation of GABA and enkephalin systems. Chronic effects (improved mood, cognitive enhancement) develop over days to weeks, consistent with BDNF-mediated neuroplasticity.
Clinical Background and Evidence
Selank was developed and clinically tested in Russia through the 1990s and 2000s, with the Institute of Molecular Genetics of the Russian Academy of Sciences leading its research program. The peptide emerged from research into tuftsin — an endogenous four-amino acid peptide released from fibrinogen that acts as an immune modulator. Selank was synthesized as a heptapeptide analog (seven amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed to combine tuftsin's immunomodulatory properties with enhanced anxiolytic effects. This hybrid profile — combining immune function enhancement with anxiety reduction — is unique among the nootropic peptides and explains Selank's broad clinical interest.
It received regulatory approval in Russia in 2001 for generalised anxiety disorder, social phobia, and neurasthenia, with approval as an intranasal spray formulation. This clinical validation is significant: unlike most Western research peptides lacking human trial data, Selank has published human clinical trials demonstrating efficacy and safety. The Russian regulatory pathway, while less stringent than FDA approval in some respects, required controlled human trials and post-approval surveillance data.
Published human clinical data shows Selank reducing anxiety scores on standard psychometric scales (Hamilton Anxiety Rating Scale, STAI state anxiety scores) compared to placebo, with effect sizes comparable to benzodiazepines in mild-to-moderate anxiety — but without sedation or memory impairment. Seredenin & Kozlovskaya's research (1999–2003) documented that Selank produced anxiolytic effects in the range of 50–70% anxiety reduction on the HAM-A scale in clinical anxiety patients, with onset within 30 minutes of intranasal administration. Critically, cognitive testing showed either no impairment or slight improvement in memory and reaction time — contrasting sharply with benzodiazepines, which typically impair cognition at anxiolytic doses.
A notable finding was improvement in learning and memory alongside anxiety reduction, which is the opposite of what benzodiazepines typically produce. This cognitive-sparing effect has been attributed to BDNF upregulation and the absence of the sedation-related cognitive blunting typical of GABA agonists. In working memory tasks, Selank-treated subjects showed no decline and in some studies slight improvement, consistent with its mild pro-cognitive profile.
In animal models, Selank demonstrated consistent anxiolytic effects in elevated plus maze and open field paradigms — classical anxiety tests. Antidepressant effects were observed in forced swim tests and chronic stress models. Importantly, the antidepressant profile developed over 10–14 days of daily administration, consistent with the timeline for BDNF-mediated neuroplasticity. Improved immune function was documented via tuftsin-related immunomodulatory activity: Selank increased T-helper cell proliferation, enhanced phagocytic capacity of macrophages, and elevated IL-2 production in response to mitogenic challenge. These immune effects occurred alongside anxiolytic effects, suggesting the dual mechanism is functionally integrated rather than separate pathways.
In neuroprotection studies, Selank reduced neuronal apoptosis in stress-induced models and showed protective effects in brain ischemia models, suggesting potential applications beyond anxiety. Uchakina et al. documented improved cognitive recovery in rats with induced mild brain damage when treated with Selank, attributed to BDNF elevation and anti-inflammatory effects. This neuroprotective angle remains understudied in the Western literature but represents a significant potential application in age-related cognitive decline and neurotrauma recovery.
What Is the Recommended Selank Dosage?
Selank dosing in the clinical literature and community protocols centres around intranasal and subcutaneous routes, with slightly different dosing conventions depending on source. The Russian clinical trials and approved formulation (Selank nasal spray) used a concentration of 75 mcg per spray with a typical clinical protocol of 2–3 sprays per nostril, 3 times daily — totalling 450–675 mcg/day. This high-frequency low-dose approach appears to maintain stable CNS penetration through the olfactory route without accumulation.
| Form | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Selank standard (intranasal) | 250–500 mcg | Intranasal | 1–3x daily | Most common protocol; equivalent to Russian 450–675 mcg/day clinical dose |
| NA-Selank (N-Acetyl Selank Amidate) | 100–250 mcg | Intranasal | 1–2x daily | More potent acetylated form; 2–3x higher potency than standard Selank |
| Selank injectable | 250–500 mcg | SubQ | 1–2x daily | Less common than intranasal; effects lag slightly (onset 1–2 hours vs 30 min intranasal) |
| Acute anxiety protocol | 500 mcg | Intranasal | As needed, not more than 3–4x/day | For situational anxiety; rapid onset (15–30 min) |
| Daily maintenance | 250–300 mcg | Intranasal | Once daily (morning or as needed) | Minimalist protocol; reports of sustained anxiolytic effect with single daily dose |
Dosing Considerations
Intranasal Administration: The olfactory route is preferred clinically for rapid CNS delivery. Selank is reconstituted in bacteriostatic water or sterile saline to a typical concentration of 1 mg/mL. Each 25–50 mcL spray delivers 25–50 mcg. For higher doses, multiple sprays are used. The key advantage of intranasal over systemic routes is direct CNS delivery via olfactory nerve axonal transport, bypassing the blood-brain barrier and first-pass hepatic metabolism. This results in rapid onset (15–30 minutes) and lower total dose requirements.
Subcutaneous Administration: Injectable Selank is used less frequently but is an option for those unable to use intranasal. Typical concentration is 1 mg/mL, dosed at 0.25–0.5 mL (250–500 mcg) via small insulin syringe. Onset is slower (1–2 hours) and effects are less pronounced than intranasal, but total bioavailability may be higher. Duration appears to be 4–6 hours based on anecdotal reports.
Half-Life and Duration: The peptide half-life in circulation is relatively short (~several minutes for the base peptide), but the pharmacodynamic effects persist for hours. This dissociation between short half-life and long effect duration is attributable to downstream gene expression changes (BDNF upregulation, enkephalin stabilisation) that persist long after the peptide itself is cleared. This is consistent with intranasal protocols spacing doses 6–8 hours apart despite rapid circulating clearance.
Cycling Protocols: Most research and clinical use follows 2–4 week cycles at therapeutic doses, followed by 1–2 week breaks. This cycling is precautionary rather than based on demonstrated tolerance, as no meaningful tolerance has been documented. Many users report sustained anxiolytic effects over weeks of daily use, but cycling is maintained as a conservative approach. Some advanced users run 6–8 week continuous protocols without reported diminishing effects, but this is less common and less well-documented.
Side Effects and Safety Profile
Selank has one of the most benign side effect profiles of any nootropic peptide. The clinical trials in Russia (enrolling hundreds of anxiety disorder patients) reported adverse events at rates comparable to or lower than placebo, a remarkable finding for an anxiolytic agent. Most research subjects and users report essentially no negative effects at standard doses — this is consistent with its clinical trial data where side effects were minimal compared to benzodiazepine comparators.
Rare or Minimal Side Effects:
- Nasal irritation: Mild transient rhinitis or nasal congestion reported in some intranasal users, typically resolving within days of use. Rotating nostril injection or switching to bacteriostatic water (vs saline) sometimes resolves this.
- Mild sedation at higher doses: Occasionally reported at doses above 500 mcg daily, particularly in individuals sensitive to GABAergic compounds. Most users describe it as relaxed-but-clear rather than sedated — distinct from benzodiazepine sedation.
- Headache: Rare, reported in less than 5% of clinical trial subjects. When reported, typically mild and transient.
- Anxiety rebound: Minimal or absent. Unlike benzodiazepines, which produce significant rebound anxiety upon discontinuation, Selank withdrawal is unreported in the literature. Some users report sustained anxiolytic effects for days after the last dose.
No Dependency or Withdrawal: This is the critical safety differentiator from benzodiazepines. No physical or psychological dependence has been documented in clinical studies or reported meaningfully in community use — a 20+ year clinical history in Russia supports this. This is attributed to Selank's allosteric modulator (rather than direct agonist) activity at GABA-A, which preserves receptor regulation and prevents downregulation. The lack of withdrawal also supports cycling flexibility: users can discontinue without medical tapering protocols.
Immunomodulatory Considerations: While Selank's immunomodulatory effects (IL-6 modulation, T-helper cell balance enhancement) are therapeutic in normal immune function, theoretical concern exists for individuals with autoimmune conditions. No clinical data documents harm in autoimmune disease, but caution is warranted. Similarly, individuals with immune compromise may benefit from Selank's immune-enhancing properties, but no human trials have specifically tested this population.
Comparison: Selank vs Benzodiazepines
| Property | Selank | Benzodiazepines |
|---|---|---|
| Mechanism | GABA-A allosteric modulator | GABA-A direct agonist |
| Sedation | None to mild at high doses | Dose-dependent, significant |
| Cognitive impairment | Absent or mild improvement | Significant memory impairment |
| Tolerance | Not documented | Rapid (days to weeks) |
| Dependence | Not documented | Significant physical dependence |
| Withdrawal | Not documented | Severe (seizures, rebound anxiety) |
| Efficacy onset | 15–30 min intranasal | 15–30 min (oral forms slower) |
| Duration | 4–6 hours | 6–12 hours (varies by agent) |
| Additional benefits | BDNF upregulation, immune enhancement | None (sedation only) |
Stacking with Other Peptides
Selank + Semax (Most Common Stack): This is the classic Russian nootropic peptide combination, approved as a marketed product ("Calm + Clarity") in some markets. Semax provides cognitive enhancement, memory improvement, and mild stimulation via dopaminergic and BDNF mechanisms. Selank provides anxiety reduction and emotional resilience. Together they cover the focus-plus-calm profile that neither achieves alone. Typical protocol: Semax (500–1000 mcg) in the morning for cognitive enhancement, Selank (250–500 mcg) 30–60 minutes before high-stress situations or once daily in the afternoon for anxiety management. This stack is synergistic rather than simply additive — users often report better overall function than either alone.
Selank + Ipamorelin: Combines anxiety reduction with GH secretion enhancement. Less common than Selank + Semax but potentially useful for individuals seeking both mood and body composition improvements. Dosing: 250–500 mcg Selank + 200–500 mcg Ipamorelin, administered together intranasal.
Selank + 5-HTP or L-Tryptophan: Potentially synergistic for serotonin-related mood enhancement. Selank's modest serotonin modulation combined with tryptophan supplementation may enhance mood effects. Minimal data on interaction; caution warranted for those with serotonin sensitivity.
Avoid Combination: Selank + direct benzodiazepines is not contraindicated pharmacologically, but the combination redundantly targets GABA-A and risks unwanted sedation. If transitioning from benzodiazepines, Selank can serve as an alternative rather than an adjunct.
Selank Applications and Use Cases
Generalized Anxiety Disorder (GAD): This is Selank's primary indication, supported by Russian clinical trials and regulatory approval. The typical presentation is chronic, moderate anxiety with intrusive thoughts, physical tension, and sleep disruption. Selank addresses all three: rapid anxiolytic effect (30 min), muscle relaxation without sedation, and improved sleep quality reported by many users. Effect sizes in clinical trials were comparable to low-dose benzodiazepines (5 mg diazepam equivalent) but without sedation or cognitive impairment.
Social Anxiety and Performance Anxiety: The community reports strong subjective benefits for social anxiety, particularly before high-stakes social situations (presentations, meetings, social gatherings). The rapid onset (15–30 min intranasal) makes it suitable for situational anxiety. Users describe reduced social avoidance, improved speech fluency, and increased comfort in interpersonal interaction. This profile — anxiety reduction without cognitive blunting or sedation — is superior to benzodiazepines for social situations requiring mental sharpness.
PTSD and Trauma-Related Anxiety: While formal PTSD trials are absent, Selank's anxiolytic and BDNF-enhancing properties are theoretically suited to trauma recovery. BDNF elevation is mechanistically relevant to PTSD recovery (supporting fear extinction learning in the prefrontal cortex). Anecdotal reports from trauma survivors describe reduced hyperarousal and improved sleep quality. No formal recommendation can be made, but research interest is warranted.
Depression as Anxiety Adjunct: Selank is not a primary antidepressant but is used as an anxiolytic adjunct in depressed patients with comorbid anxiety — a highly prevalent presentation. Its mood-elevating effects (via enkephalin stabilisation and BDNF) appear sufficient for mild depression or depression-related anxiety, though severe major depressive episodes require primary antidepressant therapy.
Cognitive Enhancement and Neuroprotection: While not a primary nootropic like Semax, Selank's cognitive-sparing profile and BDNF elevation suggest potential benefits for age-related cognitive decline, mild cognitive impairment, and brain health. The neuroprotective effects documented in animal models (protection against ischemia, apoptosis reduction) remain understudied in humans but suggest potential applications in neurotrauma recovery and age-related neurodegeneration.
Stress Resilience and Burnout Prevention: Users consistently report improved stress tolerance and recovery from chronic stress. This stress-buffering effect may reflect the combination of acute GABA-mediated calm and chronic BDNF-mediated neuroplastic resilience. For high-stress occupations or periods, Selank appears to reduce burnout risk and accelerate recovery from acute stressors.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Trusted Research-Grade Sources
Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).
Particle Peptides
Independently HPLC-tested, transparent COAs, comprehensive product range.
Browse Particle Peptides →Limitless Life Nootropics
Premium research peptides with strong customer support and verified purity.
Browse Limitless Life →Frequently Asked Questions
Selank primarily reduces anxiety through GABA-A receptor modulation and enkephalin stabilisation. Unlike benzodiazepines, it produces calming effects without sedation, cognitive blunting, or dependency risk. Additional effects include improved mood, stress resilience, and mild cognitive enhancement. It is registered as an anxiolytic medication in Russia.
No addiction or physical dependence has been documented in Selank's clinical research or community use. This distinguishes it clearly from benzodiazepines, which act on the same receptor class but cause tolerance and withdrawal through direct agonism. Selank's modulator mechanism avoids receptor downregulation.
They serve different primary purposes. Selank is best for anxiety reduction, stress resilience, and calm focus. Semax is best for cognitive enhancement, memory, and mental sharpness. They're complementary rather than competing — the most common protocol stacks both. If choosing one: use Selank for anxiety-dominant issues, Semax for cognition-dominant goals.
Most protocols use Selank daily for 2–4 week cycles. The lack of documented tolerance development makes continuous use theoretically safer than many anxiolytics, but cycling is still practiced as standard precaution. Many users report no diminishing effect over weeks of daily use.
Selank is reconstituted in bacteriostatic water or sterile saline and administered using a nasal atomizer or sterile dropper. Typical volume is 25–50 mcL per nostril. The olfactory route provides direct CNS delivery bypassing the blood-brain barrier. Avoid blowing nose for 10 minutes after dosing for maximum absorption.
Selank produces calm and reduced anxiety without meaningful sedation in most users at standard doses (250–500 mcg). This is one of its key advantages over benzodiazepines. At higher doses some users report mild relaxation that could interfere with tasks requiring alertness. Most describe the experience as anxiolysis-without-sedation.